Penzberg, Germany – Two new high-performance reagents deliver more viable cells, help accelerate cellular and molecular research efforts.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the introduction of two new highperformance DNA transfection reagents for its innovative cellular analysis portfolio for life science

research. Designed for commonly used and hard-to-transfect cell lines, the X-tremeGENE 9 and XtremeGENE HP reagents offer high efficiency, reproducibility and cell survival rates, compared to

leading transfection reagents, to deliver more viable cells and help accelerate research efforts. Both

reagents support a wide variety of cellular and molecular research applications, such as gene

expression analysis and protein production.

The two new products build on Roche’s 20 years of experience with transfection reagents. The XtremeGENE 9 reagent offers efficient performance across a wide variety of commonly used cell lines

while Roche’s X-tremeGENE HP reagent is especially well suited for cell lines that are difficult to

transfect or not easily transfected with other reagents.

Both reagents combine low cytotoxicity with high efficiency and reproducibility, providing more

viable cells with more physiologically relevant results. They also offer easy-to-implement protocols:

Researchers simply dilute the reagent, incubate it with plasmid DNA, and pipette it directly onto

cells. The simple process enables researchers to spend less time optimizing the reagent and more

time advancing their research.

Both reagents function well in the presence or absence of serum and remain stable after repeated

vial openings, helping to save researchers time and effort. More information is available at www.xtremegene.

roche.com.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with

combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech

company with truly differentiated medicines in oncology, virology, inflammation, metabolism and

CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a

pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing

medicines and diagnostic tools that enable tangible improvements in the health, quality of life and

survival of patients. In 2009, Roche had over 80’000 employees worldwide and invested almost 10

billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United

States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai

Pharmaceutical, Japan. For more information: www.roche.com.

For life science research only. Not for use in diagnostic procedures.

X-tremeGENE is a trademark of Roche.

Other brands or product names are trademarks of their respective holders.